Good day from STAT’s London outpost, with Andrew Joseph here filling in for Mr. Pharmalot. We’re taking the rate at which the sun is setting earlier and earlier as a personal affront, but guess there’s no choice but to keep grinding away, perhaps fueled by an extra cup of stimulation. Maybe some headlines can also do the trick.…
Two affiliated Chinese drug manufacturers targeted by forthcoming U.S. national security legislation are working on sales of some of their operations, the Financial Times reports, citing people familiar with the matter. WuXi AppTec and WuXi Biologics are among five China-based companies targeted by the Biosecure Act, which would ban drugmakers with U.S. government contracts from using the Chinese groups’ services after 2032. The bipartisan bill overwhelmingly passed the House and is making its way through the Senate.
The U.S. government will provide more time for negotiations and more chances for drugmakers to submit counter offers during the second round of talks over price cuts for its Medicare program, Reuters writes. By Feb. 1, 2025, the Centers for Medicare and Medicaid Services will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027. The agency will now meet with drugmakers before making its initial offer, and will hold one of the three allotted negotiation meetings before the deadline for the first counter offer. If a company chooses to counter the government’s offer, it will have two further meetings to negotiate.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
